Factors predicting for urinary incontinence after prostate brachytherapy

McElveen, T.L.; Waterman, Frank M.; Kim, Hayeon; Dicker, Adam P.

doi:10.1016/j.ijrobp.2004.01.050

Cited by 30 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the absence of a TURP cavity urinary incontinence, following I-125 seed brachytherapy has been related to urethral dose and pre-implant urinary symptom score (IPSS). In a detailed study of I-125 monotherapy delivering 145 Gy, the mean urethral D 10 in patients having no urinary toxicity was 314 Gy compared to 394 Gy in those with any grade of incontinence; the incidence doubled in patients who received a dose of > 450 Gy [10]. Current GEC-ESTRO guidelines recommend that the urethral D 10 is kept below 150% i.e.…”

Section: Discussionmentioning

confidence: 99%

Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection

Salembier¹,

Rijnders²,

Henry³

et al. 2013

jcb

View full text Add to dashboard Cite

PurposeTo evaluate in a multicenter setting the ability of centers to perform pre-implant permanent prostate brachytherapy planning, fulfilling dosimetric goals and constraints based on the Groupe de Curiethérapie-European Society for Radiotherapy and Oncology guidelines in the setting of implantation after prior prostate transurethral resection (TURP).Material and methodsA reference transrectal ultrasound image set of the prostate gland from a patient who had undergone TURP was used. Contouring of the prostate, clinical target volume and organs at risk was performed by the coordinating center. Goals and constraints regarding the dosimetry were defined.ResultsSeventeen of twenty-five centers invited to participate were able to import the Digital Imaging and Communications in Medicine-images into their planning computer and plan the implant using the defined guidelines. All centers were able to plan treatment, and achieve the recommended objectives and constraints. However, sector analysis has shown a risk of under-dosage in the anterior part of the prostate.ConclusionsCorrect pre-implantation planning with adherence to protocol guidelines and in compliance with defined dosimetric constraints seems feasible in a post-TURP setting, at least on a theoretical basis. A prospective study evaluating the outcome of prostate brachytherapy performed after TURP can therefore be undertaken with an expectation of a correct dosimetry in the multicenter setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection

Salembier¹,

Rijnders²,

Henry³

et al. 2013

jcb

View full text Add to dashboard Cite

show abstract

“…T. L. McEleveen ir kt. duomenimis, predikciniai inkontinencijos veiksniai po I-125 brachiterapijos yra dozė šlaplėje (šlaplės D90) ir prieš implantaciją buvęs PSA kiekis (35). 153 ligoniai buvo gydyti I-125 brachiterapija (D90 145 Gy doze): G1 šlapinimosi sutrikimai diagnozuoti 26 proc.…”

Section: šLaplės Pažeidimasunclassified

“…pacientų. Vienveiksne ir daugiaveiksne analize nustatyti tik du veiksniai, turintys įtakos dažnesniems erekcijos sutrikimams: priešinės liaukos dozė (D90 >160 Gy) ir prieš brachiterapiją buvusi blogesnė lytinė funkcija (≥G2) (35). J.…”

Section: Erekcijos Sutrikimaiunclassified

Review on the effectiveness of prostate cancer brachytherapy

Inčiūra¹,

Jarusevicus²,

Vaičiūnas³

et al. 2009

Medicina

View full text Add to dashboard Cite

show abstract

“…Perhaps the incidence of postradiotherapy incontinence could be improved with proper patient selection. Suggestions for lowering the risk of incontinence include selecting patients with a preprocedure IPSS score of less than 15 and keeping the urethral dose administered with 125 I at prescribed doses [23].…”

Section: Corticosteroidsmentioning

confidence: 99%